Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects
Authors:
- 1 April 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 18 (4) , 531-539
Abstract
(2009). Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects. Expert Opinion on Investigational Drugs: Vol. 18, No. 4, pp. 531-539. doi: 10.1517/13543780902849244Keywords
This publication has 38 references indexed in Scilit:
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Evidence for a Role of Superoxide Generation in Glucose-Induced β-Cell Dysfunction In VivoDiabetes, 2007
- Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067Journal of Clinical Lipidology, 2007
- Inflammation and insulin resistanceJournal of Clinical Investigation, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery diseaseThe American Journal of Cardiology, 2003
- Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemiaJACC, 2002
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)The American Journal of Cardiology, 1994
- Effect of Probucol on Recovery from Streptozotocin Diabetes in RatsHormone and Metabolic Research, 1992